116 related articles for article (PubMed ID: 34214591)
1. Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway.
Rahmani F; Hashemzehi M; Avan A; Barneh F; Asgharzadeh F; Moradi Marjaneh R; Soleimani A; Parizadeh M; Ferns GA; Ghayour Mobarhan M; Ryzhikov M; Afshari AR; Ahmadian MR; Giovannetti E; Jafari M; Khazaei M; Hassanian SM
Cell Signal; 2021 Sep; 85():110069. PubMed ID: 34214591
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of
Zhou X; Xiao Q; Fu D; Zhang H; Tang Y; He J; Hu Y; Kong X; Teng F; Liu X; Yuan Y; Ding K
Cancer Biol Med; 2021 Aug; 19(2):213-28. PubMed ID: 34347396
[TBL] [Abstract][Full Text] [Related]
3. Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways.
Rahmani F; Asgharzadeh F; Avan A; Barneh F; Parizadeh MR; Ferns GA; Ryzhikov M; Ahmadian MR; Giovannetti E; Jafari M; Khazaei M; Hassanian SM
Life Sci; 2020 May; 249():117470. PubMed ID: 32135184
[TBL] [Abstract][Full Text] [Related]
4. Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cells.
Zhou X; Fu D; Yang H; Le C; Lu Y; Wei J; Tang Y; Zhang J; Yuan Y; Ding K; Xiao Q
Cancer Lett; 2023 Nov; 577():216422. PubMed ID: 37805162
[TBL] [Abstract][Full Text] [Related]
5. Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
Qin H; Jiang Y; Zhang J; Deng C; Zhong Z
Mol Pharm; 2019 Aug; 16(8):3711-3719. PubMed ID: 31299161
[TBL] [Abstract][Full Text] [Related]
6. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway.
Lin W; Zheng L; Zhuang Q; Zhao J; Cao Z; Zeng J; Lin S; Xu W; Peng J
BMC Complement Altern Med; 2013 Jun; 13():144. PubMed ID: 23800091
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of DJ-1 enhances colorectal cancer cell proliferation through the cyclin-D1/MDM2-p53 signaling pathway.
Zhu X; Luo C; Lin K; Bu F; Ye F; Huang C; Luo H; Huang J; Zhu Z
Biosci Trends; 2020 May; 14(2):83-95. PubMed ID: 32132307
[TBL] [Abstract][Full Text] [Related]
8. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
[TBL] [Abstract][Full Text] [Related]
9. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
10. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
[TBL] [Abstract][Full Text] [Related]
11. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
12. Verbascoside promotes apoptosis by regulating HIPK2-p53 signaling in human colorectal cancer.
Zhou L; Feng Y; Jin Y; Liu X; Sui H; Chai N; Chen X; Liu N; Ji Q; Wang Y; Li Q
BMC Cancer; 2014 Oct; 14():747. PubMed ID: 25282590
[TBL] [Abstract][Full Text] [Related]
13. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
14. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
15. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
17. RasGRF2 promotes migration and invasion of colorectal cancer cells by modulating expression of MMP9 through Src/Akt/NF-κB pathway.
Lu P; Chen J; Yan L; Yang L; Zhang L; Dai J; Hao Z; Bai T; Xi Y; Li Y; Kang Z; Xv J; Sun G; Yang T
Cancer Biol Ther; 2019; 20(4):435-443. PubMed ID: 30359168
[TBL] [Abstract][Full Text] [Related]
18. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
19. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
20. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
